PDF(Sci-hub)
Abstract：
Patients with diabetes commonly experience hyposalivation, which induces discomfort in eating, swallowing, dryness, smell, and speaking, as well as increases the incidence of periodontal disease. Dipeptidyl peptidase-4 (DPP4) inhibitors are frequently used as antidiabetic drugs that lower glucose levels by utilizing similar mechanisms; however, additional protective functions of each gliptin have been discovered. In this study, the protective roles of gemigliptin, a DPP4 inhibitor, against salivary dysfunction under diabetic conditions were investigated. Streptozotocin-induced diabetic rats received gemigliptin 10 mg/kg or 100 mg/kg via oral gavage for 3 weeks. The weights of salivary gland tissues, saliva secretion, and antioxidant capacity in salivary glands were reduced after diabetes induction, but were significantly preserved following gemigliptin treatment. In salivary gland analysis, expression of apoptotic proteins, as well as amylase and aquaporin-5 (AQP5) protein expression, were increased following gemigliptin treatment. Furthermore, the number of TUNEL-positive cells decreased after gemigliptin treatment. Therefore, gemigliptin has protective roles against salivary dysfunction observed in diabetes, mediated via antioxidant, anti-apoptotic, and salivary secretion mechanisms. These results may help in selecting a suitable drug for patients with diabetes experiencing salivary dysfunction.
摘要：
糖尿病患者通常会出现唾液分泌减少，这会导致饮食不适，吞咽,干燥度,气味,说话,以及增加牙周病的发病率。二肽基肽酶-4（DPP4）抑制剂经常用作抗糖尿病药物，通过利用类似的机制降低葡萄糖水平；然而，已经发现了每种格列汀的额外保护功能。在这项研究中,吉格列汀的保护作用，一种DPP4抑制剂，对糖尿病患者的唾液功能障碍进行了研究。链脲佐菌素诱导的糖尿病大鼠通过口服管饲法接受10mg/kg或100mg/kg的吉格列汀3周。唾液腺组织的重量，唾液分泌,糖尿病诱导后唾液腺的抗氧化能力降低，但在吉格列汀治疗后显著保留。在唾液腺分析中，凋亡蛋白的表达，以及淀粉酶和水通道蛋白-5（AQP5）蛋白的表达，吉格列汀治疗后增加。此外，吉格列汀治疗后TUNEL阳性细胞数量减少.因此,吉格列汀对糖尿病患者唾液功能障碍具有保护作用，通过抗氧化剂介导，抗凋亡，和唾液分泌机制。这些结果可能有助于为患有唾液功能障碍的糖尿病患者选择合适的药物。
